デフォルト表紙
市場調査レポート
商品コード
1043069

幹細胞治療の世界市場:細胞源別、タイプ別、アプリケーション別、エンドユーザー別、地域別の情報-2027年までの予測

Stem Cell Therapy Market: Information by Cell Source, by Type, by Application, by End User, and by Region -Forecast till 2027

出版日: | 発行: Market Research Future | ページ情報: 英文 132 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
幹細胞治療の世界市場:細胞源別、タイプ別、アプリケーション別、エンドユーザー別、地域別の情報-2027年までの予測
出版日: 2021年08月01日
発行: Market Research Future
ページ情報: 英文 132 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の幹細胞治療の市場規模は、2020年に57億3,512万米ドルとなり、2020年から2027年までの予測期間中、10.74%のCAGRを達成すると予想されています。

市場の成長は、慢性疾患の増加、ヘルスケア産業の拡大、医療研究への支出の増加に起因しています。さらに、幹細胞治療に関する臨床研究の数が増えていることも、市場の成長を促進しています。しかし、初期段階の幹細胞を用いた治療には倫理的な問題がつきまとい、また多額の費用がかかるため、将来的に市場の発展を妨げる可能性があります。

当レポートでは、世界の幹細胞治療市場について調査分析し、市場力学、市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートプロローグ

第2章 市場のイントロダクション

  • 定義
  • 調査範囲
    • 調査目的
    • 仮定
    • 制限

第3章 調査手法

  • イントロダクション
  • 1次調査
  • 2次調査
  • 市場規模の推定

第4章 市場力学

  • 促進要因
  • 抑制要因
  • 市場機会
  • 課題
  • マクロ経済指標
  • 技術の動向と評価

第5章 市場要因分析

  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • バリューチェーン分析
  • 投資実現可能性分析
  • 価格分析

第6章 世界の幹細胞治療市場:タイプ別

  • イントロダクション
  • 同種異系
  • 自家

第7章 世界の幹細胞治療市場:治療法別

  • イントロダクション
  • 薬物療法
  • 心血管疾患
  • 骨の再生
  • 神経変性疾患
  • 創傷治癒
  • 目の治療
  • 造血系疾患
  • 代謝障害
  • 免疫不全
  • 糖尿病

第8章 世界の幹細胞治療市場:細胞源別

  • イントロダクション
  • 脂肪組織
  • 骨髄
  • 神経
  • 胚/臍帯血由来
  • IPSCS

第9章 世界の幹細胞治療市場:エンドユーザー別

  • イントロダクション
  • バイオテクノロジー企業
  • 病院および研究機関
  • 受託研究機関
  • 幹細胞バンク

第10章 世界の幹細胞治療市場:地域別

  • イントロダクション
  • 米国
    • 北米
    • 南米
  • 欧州
    • 西欧
    • 東欧
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 大韓民国
    • その他のアジア太平洋
  • 中東・アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • オマーン
    • クウェート
    • カタール
    • その他

第11章 企業情勢

  • イントロダクション
  • 市場シェア分析
  • 主な開発と戦略
    • 主な開発

第12章 企業プロファイル

  • OSIRIS THERAPEUTICS, INC.
    • 企業概要
    • 製品タイプの概要
    • 財務
    • 主な開発
    • SWOT分析
  • MEDIPOST CO., LTD.
    • 企業概要
    • 製品タイプの概要
    • 財務概要
    • 主な開発
    • SWOT分析
  • ANTEROGEN CO., LTD.
    • 企業概要
    • 製品タイプの概要
    • 財務概要
    • 主な開発
    • SWOT分析
  • PHARMICELL CO., LTD.
    • 企業概要
    • 製品タイプ/事業セグメントの概要
    • 財務概要
    • 主な開発
    • SWOT分析
  • HOLOSTEM TERAPIE AVANZATE S.R.L.
    • 企業概要
    • 製品タイプの概要
    • 財務概要
    • 主な開発
    • SWOT分析
  • JCR PHARMACEUTICALS CO., LTD.
    • 企業概要
    • 製品タイプの概要
    • 財務概要
    • 主な開発
    • SWOT分析
  • NUVASIVE, INC
    • 概要
    • 製品タイプの概要
    • 財務
    • 主な開発
    • SWOT分析
  • RTI SURGICAL, INC.
    • 概要
    • 製品タイプの概要
    • 財務
    • 主な開発
    • SWOT分析
  • ALLOSOURCE
    • 概要
    • 製品タイプの概要
    • 財務
    • 主な開発
    • SWOT分析
  • THERMO FISHER SCIENTIFIC
    • 概要
    • 製品タイプの概要
    • 財務
    • 主な開発
    • SWOT分析
  • その他

第13章 付録

図表

LIST OF TABLES

  • TABLE 1 STEM CELL THERAPY MARKET INDUSTRY SYNOPSIS, 2020-2027
  • TABLE 2 GLOBAL STEM CELL THERAPY MARKET ESTIMATES & FORECAST, 2020-2027, (USD MILLION)
  • TABLE 3 GLOBAL STEM CELL THERAPY MARKET, BY REGION, 2020-2027, (USD MILLION)
  • TABLE 4 GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 5 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 7 GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 8 GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION
  • TABLE 9 NORTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 10 NORTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 12 NORTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 13 NORTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 14 US: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 15 US: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 17 US: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 18 US: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 19 CANADA: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 20 CANADA: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 22 CANADA: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 23 CANADA: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 24 SOUTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 25 SOUTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 27 SOUTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 28 SOUTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 29 EUROPE: GLOBAL STEM CELL THERAPY MARKET, TYPE, 2020-2027, (USD MILLION)
  • TABLE 30 EUROPE: GLOBAL STEM CELL THERAPY MARKET, THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 32 EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 33 EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 34 WESTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 35 WESTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 37 WESTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 38 WESTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION
  • TABLE 39 EASTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 40 EASTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 42 EASTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 43 EASTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 44 ASIA-PACIFIC: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 45 ASIA-PACIFIC: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 47 ASIA-PACIFIC: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 48 ASIA-PACIFIC: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 49 MIDDLE EAST & AFRICA: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 50 MIDDLE EAST & AFRICA: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 52 MIDDLE EAST & AFRICA: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 53 MIDDLE EAST & AFRICA: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 RESEARCH PROCESS
  • FIGURE 2 SEGMENTATION FOR THE GLOBAL STEM CELL THERAPY MARKET
  • FIGURE 3 MARKET DYNAMICS FOR GLOBAL STEM CELL THERAPY MARKET
  • FIGURE 4 GLOBAL STEM CELL THERAPY MARKET SHARE, BY TYPE 2020
  • FIGURE 4 GLOBAL STEM CELL THERAPY MARKET SHARE, BY PRODUCT TYPE 2020
  • FIGURE 5 GLOBAL STEM CELL THERAPY MARKET SHARE, BY CELL SOURCE 2020
  • FIGURE 6 GLOBAL STEM CELL THERAPY MARKET SHARE, BY END-USER, 2020
  • FIGURE 7 GLOBAL STEM CELL THERAPY MARKET SHARE, BY REGION, 2020
  • FIGURE 8 NORTH AMERICA STEM CELL THERAPY MARKET SHARE, BY COUNTRY, 2020
  • FIGURE 9 EUROPE STEM CELL THERAPY MARKET SHARE, BY COUNTRY, 2020
  • FIGURE 10 ASIA-PACIFIC STEM CELL THERAPY MARKET SHARE, BY COUNTRY, 2020
  • FIGURE 11 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SHARE, BY COUNTRY, 2020
  • FIGURE 12 GLOBAL STEM CELL THERAPY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
  • FIGURE 13 OSIRIS THERAPEUTICS, INC.: KEY FINANCIALS
  • FIGURE 14 OSIRIS THERAPEUTICS, INC.: SEGMENTAL REVENUE
  • FIGURE 15 OSIRIS THERAPEUTICS, INC.: GEOGRAPHICAL REVENUE
  • FIGURE 16 MEDIPOST CO., LTD.: KEY FINANCIALS
  • FIGURE 17 MEDIPOST CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 18 MEDIPOST CO., LTD.: GEOGRAPHICAL REVENUE
  • FIGURE 19 ANTEROGEN CO., LTD.: KEY FINANCIALS
  • FIGURE 20 ANTEROGEN CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 21 ANTEROGEN CO., LTD.: GEOGRAPHICAL REVENUE
  • FIGURE 22 PHARMICELL CO., LTD.: KEY FINANCIALS
  • FIGURE 23 PHARMICELL CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 24 PHARMICELL CO., LTD.: GEOGRAPHICAL REVENUE
  • FIGURE 25 JCR PHARMACEUTICALS CO., LTD.: KEY FINANCIALS
  • FIGURE 26 JCR PHARMACEUTICALS CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 27 JCR PHARMACEUTICALS CO., LTD.: GEOGRAPHICAL REVENUE
  • FIGURE 28 HOLOSTEM TERAPIE AVANZATE S.R.L.: KEY FINANCIALS
  • FIGURE 29 HOLOSTEM TERAPIE AVANZATE S.R.L. : SEGMENTAL REVENUE
  • FIGURE 30 HOLOSTEM TERAPIE AVANZATE S.R.L.: GEOGRAPHICAL REVENUE
  • FIGURE 31 NUVASIVE, INC: KEY FINANCIALS
  • FIGURE 32 NUVASIVE, INC: SEGMENTAL REVENUE
  • FIGURE 33 NUVASIVE, INC: GEOGRAPHICAL REVENUE
  • FIGURE 34 RTI SURGICAL, INC.: KEY FINANCIALS
  • FIGURE 35 RTI SURGICAL, INC.: SEGMENTAL REVENUE
  • FIGURE 36 RTI SURGICAL, INC.: GEOGRAPHICAL REVENUE
  • FIGURE 37 ALLOSOURCE: KEY FINANCIALS
  • FIGURE 38 ALLOSOURCE: SEGMENTAL REVENUE
  • FIGURE 39 ALLOSOURCE: GEOGRAPHICAL REVENUE
  • FIGURE 40 THERMO FISHER SCIENTIFIC: KEY FINANCIALS
  • FIGURE 41 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE
  • FIGURE 42 THERMO FISHER SCIENTIFIC: GEOGRAPHICAL REVENUE
目次
Product Code: MRFR/HC/4961-CR

Global Stem Cells Therapy Market Forecast till 2027

Market Overview

The stem cell therapy market is expected to attain a significant CAGR of 10.74% during the review period of 2020 to 2027. Stem cell therapy is used to cure any disease. The global market growth is attributed to the rising prevalence of chronic diseases, expanding healthcare industry, and the growing expenditure on medical research. Additionally, the increasing number of clinical studies for stem cell therapy are fuelling the global market growth during the review period.

The global stem cells therapy market is expected to register a healthy market expansion during the forecast period owing to the largest market value of USD 5,735.12 million in 2020. Moreover, an increment in the number of clinical investigations for stem cell therapy is, driving the market development. In any case, the moral worries identified with early-stage stem cell-based treatments and the related significant expenses might hamper the stem cell therapy market development in the future.

Market Segmentation

The stem cell therapy market has been classified in terms of cell source, type, application, and end-user.

Based on cell source the market is classified into adipose tissue, bone marrow, embryo/cord blood-derived, neural, IPSCs, and PSCs.

Based on type, the stem cell therapy market is divided into allogenic and autologous.

By application, the market is classified into diabetes, musculoskeletal disorders, cancer, cardiovascular disorders, gastrointestinal diseases, and others.

In terms of end-user, the global market is categorized into hospitals & clinics, academic research centers, and others.

Regional Analysis

Geographically the stem cell therapy market is spread across the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The expanded public-private financing and exploration awards for delivering protected and successful stem cell therapy items and the presence of central members in the locale are the main considerations driving America's stem cell therapy market.

Europe holds the second biggest portion of the overall industry because of an increment in the eagerness of patients to go through stem cell therapy and a developing number of instances of persistent and neurological problems.

Asia-Pacific is the quickest developing territorial market for stem cell treatments as it is growing quickly and has seen the rise of numerous players. In addition, the rising pervasiveness of disease, and developing reception of stem cell therapy medicines in the area, are probably going to drive the market's development.

The stem cell therapy market in the Middle East& Africa is relied upon to observe confined development because of an absence of public mindfulness and restricted reasonableness among the populace. Be that as it may, some regenerative medication applications are occurring in the Gulf nations.

Major Players

The key companies listed in the stem cell therapy market report Seraxis, Inc. (Germany), ViaCyte, Inc. (the US), Betalin Therapeutics Ltd (Israel), 4.NextCell Pharma AB (US), Kadimastem (Israel), Vertex Pharmaceuticals (US), Fresenius Medical Care AG & Co. KGaA (Germany), Sernava Corp (Canada), Novo Nordisk A/S (Denmark), and Generex Biotechnology (Canada).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

CHAPTER 1. REPORT PROLOGUE

CHAPTER 2. MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
    • 2.2.1 RESEARCH OBJECTIVE
    • 2.2.2 ASSUMPTIONS
    • 2.2.3 LIMITATIONS

CHAPTER 3. RESEARCH METHODOLOGY

  • 3.1 INTRODUCTION
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION

CHAPTER 4. MARKET DYNAMICS

  • 4.1 DRIVERS
  • 4.2 RESTRAINTS
  • 4.3 OPPORTUNITIES
  • 4.4 CHALLENGES
  • 4.5 MACROECONOMIC INDICATORS
  • 4.6 TECHNOLOGY TRENDS & ASSESSMENT

CHAPTER 5. MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 VALUE CHAIN ANALYSIS
  • 5.3 INVESTMENT FEASIBILITY ANALYSIS
  • 5.4 PRICING ANALYSIS

CHAPTER 6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 ALLOGENEIC
  • 6.3 AUTOLOGOUS

CHAPTER 7. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 MEDICINE
  • 7.3 CARDIOVASCULAR DISEASES
  • 7.4 BONE REGENERATION
  • 7.5 NEURODEGENERATIVE DISORDERS
  • 7.6 WOUND HEALING
  • 7.7 TREATMENT OF EYES
  • 7.8 HEMATOPOIETIC DISORDERS
  • 7.9 METABOLIC DISORDERS
  • 7.10 CANCER
  • 7.11 IMMUNODEFICIENCY
  • 7.12 DIABETES

CHAPTER 8. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE

  • 8.1 INTRODUCTION
  • 8.2 ADIPOSE TISSUE
  • 8.3 BONE MARROW
  • 8.3 NEURAL
  • 8.4 EMBRYO/CORD BLOOD-DERIVED
  • 8.5 IPSCS

CHAPTER 9. GLOBAL STEM CELL THERAPY MARKET, BY END -USER

  • 9.1 INTRODUCTION
  • 9.2 BIOTECHNOLOGY COMPANIES
  • 9.3 HOSPITALS & RESEARCH INSTITUTES
  • 9.4 CONTRACT RESEARCH ORGANIZATIONS
  • 9.5 STEM CELL BANKS

CHAPTER 10. GLOBAL STEM CELL THERAPY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 AMERICA
    • 10.2.1 NORTH AMERICA
      • 10.2.1.1 US
      • 10.2.1.2 CANADA
    • 10.2.2 SOUTH AMERICA
  • 10.3 EUROPE
    • 10.3.1 WESTERN EUROPE
      • 10.3.1.1 GERMANY
      • 10.3.1.2 FRANCE
      • 10.3.1.3 ITALY
      • 10.3.1.4 SPAIN
      • 10.3.1.5 UK
      • 10.3.1.6 REST OF WESTERN EUROPE
    • 10.3.2 EASTERN EUROPE
  • 10.4 ASIA-PACIFIC
    • 10.4.1 JAPAN
    • 10.4.2 CHINA
    • 10.4.3 INDIA
    • 10.4.4 AUSTRALIA
    • 10.4.5 REPUBLIC OF KOREA
    • 10.4.6 REST OF ASIA-PACIFIC
  • 10.5 MIDDLE EAST & AFRICA
    • 10.5.1 UNITED ARAB EMIRATES
    • 10.5.2 SAUDI ARABIA
    • 10.5.3 OMAN
    • 10.5.4 KUWAIT
    • 10.5.5 QATAR
    • 10.5.6 REST OF THE MIDDLE EAST & AFRICA

CHAPTER 11. COMPANY LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS
  • 11.3 KEY DEVELOPMENT & STRATEGIES
    • 11.3.1 KEY DEVELOPMENTS

CHAPTER 12 COMPANY PROFILES

  • 12.1 OSIRIS THERAPEUTICS, INC.
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 PRODUCT TYPE OVERVIEW
    • 12.1.3 FINANCIALS
    • 12.2.4 KEY DEVELOPMENTS
    • 12.1.5 SWOT ANALYSIS
  • 12.2 MEDIPOST CO., LTD.
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 PRODUCT TYPE OVERVIEW
    • 12.2.3 FINANCIAL OVERVIEW
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 SWOT ANALYSIS
  • 12.3 ANTEROGEN CO., LTD.
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 PRODUCT TYPE OVERVIEW
    • 12.3.3 FINANCIAL OVERVIEW
    • 12.3.4 KEY DEVELOPMENT
    • 12.3.5 SWOT ANALYSIS
  • 12.4 PHARMICELL CO., LTD.
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 PRODUCT TYPE/BUSINESS SEGMENT OVERVIEW
    • 12.4.3 FINANCIAL OVERVIEW
    • 12.4.4 KEY DEVELOPMENT
    • 12.4.5 SWOT ANALYSIS
  • 12.5 HOLOSTEM TERAPIE AVANZATE S.R.L.
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 PRODUCT TYPE OVERVIEW
    • 12.5.3 FINANCIAL OVERVIEW
    • 12.5.4 KEY DEVELOPMENTS
    • 12.5.5 SWOT ANALYSIS
  • 12.6 JCR PHARMACEUTICALS CO., LTD.
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 PRODUCT TYPE OVERVIEW
    • 12.6.3 FINANCIAL OVERVIEW
    • 12.6.4 KEY DEVELOPMENTS
    • 12.6.5 SWOT ANALYSIS
  • 12.7 NUVASIVE, INC
    • 12.7.1 OVERVIEW
    • 12.7.2 PRODUCT TYPE OVERVIEW
    • 12.7.3 FINANCIALS
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 SWOT ANALYSIS
  • 12.8 RTI SURGICAL, INC.
    • 12.8.1 OVERVIEW
    • 12.8.2 PRODUCT TYPE OVERVIEW
    • 12.8.3 FINANCIALS
    • 12.8.4 KEY DEVELOPMENTS
    • 12.8.5 SWOT ANALYSIS
  • 12.9 ALLOSOURCE
    • 12.9.1 OVERVIEW
    • 12.9.2 PRODUCT TYPE OVERVIEW
    • 12.9.3 FINANCIALS
    • 12.9.4 KEY DEVELOPMENTS
    • 12.9.5 SWOT ANALYSIS
  • 12.10 THERMO FISHER SCIENTIFIC
    • 12.10.1 OVERVIEW
    • 12.10.2 PRODUCT TYPE OVERVIEW
    • 12.10.3 FINANCIALS
    • 12.10.4 KEY DEVELOPMENTS
    • 12.10.5 SWOT ANALYSIS
  • 12.11 OTHERS

CHAPTER 14 APPENDIX